Innovate Biopharmaceuticals, Inc. Presenting at Cowen Healthcare Conference Monday, March 7, 2016, and at Future Leaders in the Biotech Industry Friday, March 11, 2016
RALEIGH, N.C., Feb. 25, 2016 -- Innovate Biopharmaceuticals Inc., a clinical stage biotechnology company focused on gastroenterology, has been invited to present at two life science conferences in March.
Innovate will make a presentation during the Cowen and Company 36th Annual Health Care Conference at 9:30AM on Monday, March 7, 2016,and meet with interested investors throughout the conference. The Cowen Conference runs March 7 - 9, 2016,andtakes place at The Boston Marriott Copley Place.
At the Future Leaders in the Biotech Industry Conference Innovate's presentation is at 11:30AM on Friday, March 11, 2016,in Room 402/403 with a breakout session from 12:00PM-12:30PM in Room 401. The Future Leaders Conference will be held at the Millennium Broadway Hotel in New York City.
Contact us via email to schedule meetingsduring these conferences.
About Innovate Biopharmaceuticals, Inc.
Innovateis a privately held, clinical stage biotechnology company focused on developing novel gastroenterology medicines. Innovate's lead drug candidate, INN-202, is a novel oral peptide that has consistently shown to reduce clinical symptoms of celiac disease in multiple clinical trials testing more than 800 patients. INN-202 has completed a large phase IIB study and will start Phase III trials in 2016. Innovate's other therapeutic in clinical development, INN-108, is an oral small molecule entering Phase II trials for the treatment of an adult orphan indication as well as mild to moderate ulcerative colitis.INN-108 is a prodrug that only becomes activated in the colon. This therapeutic's convenience of a liquid formulation will be important to children and the aging population.
Forward Looking Statements
This release contains forward-looking statements, including statements regarding the clinical development of our product candidates which are subject to risks and uncertainties that could cause actual results to differ materially.Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongstothers. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.